In patients with PMO, zoledronate and pamidronate are associated with significantly less nephrotoxicity, which undoubtedly relates to the lower doses and longer dosing intervals employed for this indication. Ibandronate is approved in the US for treatment of PMO and in Europe for treatment of PMO and malignancy-associated bone disease. Available data suggest that ibandronate has a safe renal profile without evidence of nephrotoxicity, even in patients with abnormal
baseline kidney function.”
“The p62 protein has been identified as a major component of the protein aggregations associated with neurodegenerative disease. Oxidative insult has also been identified as a principal cause of neurodegenerative disease. Thus, in the present study, we investigated the potential role of p62 in oxidative stress-induced selleck chemicals cell death in SH-SY5Y human neuroblastoma cells. The results indicated that H2O2 treatment induced p62 expression in SH-SY5Y cells. In addition, p62 showed neuroprotective effects against H2O2-induced cell death
in differentiated SH-SY5Y cells. p62 expression prolonged Akt phosphorylation during the later stages of H2O2-induced cell death. Furthermore, coexpression of p62 and wild-type PDK1. the upstream kinase of Akt, further increased Akt phosphorylation and cell viability. whereas the expression of kinase-defective PDK1 reversed the cytoprotective effects of p62 under oxidative stress. Overexpression of p62 led to the dissociation of PDK1 from the 14-3-3 theta protein, which is thought to be selleck compound a negative regulator of PDK1 kinase activity. These findings suggest a mechanism that involves the p62-mediated modulation Of the interaction between signaling molecules and results in cell survival. (c) 2008 Elsevier Ireland Ltd. All rights reserved.”
“The
Alisertib mw renal renin-angiotensin system plays a major role in determining the rate of chronic renal disease progression. Treatment with activators of the vitamin D receptor retards the progression of experimental chronic renal disease, and vitamin D is known to suppress the renin-angiotensin system in other organs. Here we determined if the beneficial effects of paricalcitol (19-nor 1,25-dihydroxyvitamin D(2)) were associated with suppression of renin-angiotensin gene expression in the kidney. Rats with the remnant kidney model of chronic renal failure (5/6 nephrectomy) were given two different doses of paricalcitol thrice weekly for 8 weeks. Paricalcitol was found to decrease angiotensinogen, renin, renin receptor, and vascular endothelial growth factor mRNA levels in the remnant kidney by 30-50 percent compared to untreated animals. Similarly, the protein expression of renin, renin receptor, the angiotensin type 1 receptor, and vascular endothelial growth factor were all significantly decreased.